China's investigation into alleged corruption at pharmaceutical multi-nationals has widened in recent days. GlaxoSmithKline (GSK), accused last week of paying over $400m in bribes to doctors and lawyers to boost sales, admitted this week that senior executives "appear to have acted outside our processes and controls, which breaches Chinese law". Meanwhile, three AstraZeneca sales executives have been arrested, although the group was claiming early this week that they had no reason to believe the swoop was related to the bribery allegations.
What the commentators said
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
High earners underestimate how much they need to retire comfortablyHigh net worth individuals grossly misjudge how much money they need for a comfortable retirement, new data shows, with many not saving enough.
-
Retired banker who gave wife £80m to avoid inheritance tax won’t face equal split in divorceFamily lawyers say the Supreme Court ruling will have significant impact on high net worth divorce cases
-
Are GSK’s legal troubles a threat to the firm’s survival?Analysis Pharmaceutical giant GlaxoSmithKline is facing legal action over heartburn drug Zantac that has seen billions wiped off its market value. Rupert Hargreaves looks at how it might affect the business's prospects.
-
GlaxoSmithKline’s first-quarter figures show the company is on track for the yearAnalysis Latest results show that it's business as usual for pharmaceutical giant GlaxoSmithKline. Rupert Hargreaves casts his eyes over the numbers.
-
Why GSK should turn down Unilever’s billionsNews Unilever has offered GSK £50bn for its consumer division. But while the cash will be a temptation, the deal is not in the interests of shareholders or of anyone else, says Matthew Lynn.
-
Unilever slides and GSK bounces after GSK knocks back £50bn bidNews Unilever shares fell to their lowest level in around five years, after its £50bn takeover bid for GSK’s consumer health unit was rejected.
-
Shake-up at GSK won’t placate investorsNews GSK has launched a radical shakeup of its operations, but that's unlikely to satisfy investors unhappy with the drugmaker's perennial underperformance.
-
Activist investor Elliott takes takes a stake in GlaxoNews Elliott, s US hedge fund, took an undisclosed multibillion-pound stake in GSK last week, driving the share price up by 4.6%.
-
If you'd invested in: Renishaw and GlaxoSmithKlineFeatures Measuring-equipment maker Renishaw has seen profits leap, but investors are sceptical about the prospects for drugmaker GSK.
-
GSK: on the mend?Features Glaxo’s chief executive has stepped down after nine years at the top. Has he left the pharma giant in good health? Alex Rankine reports.
